首页> 外文期刊>Journal of cellular biochemistry. >In Vitro Antitumor Effects of AHR Ligands Aminoflavone (AFP 464) and Benzothiazole (5F 203) in Human Renal Carcinoma Cells
【24h】

In Vitro Antitumor Effects of AHR Ligands Aminoflavone (AFP 464) and Benzothiazole (5F 203) in Human Renal Carcinoma Cells

机译:AHR配体Aminoflavone(AFP 464)和苯并噻唑(5F 203)在人肾癌细胞中的体外抗肿瘤作用

获取原文
获取原文并翻译 | 示例
           

摘要

ABSTRACT We investigated activity and mechanism of action of two AhR ligand antitumor agents, AFP 464 and 5F 203 on human renal cancer cells, specifically examining their effects on cell cycle progression, apoptosis, and migration. TK‐10, SN12C, Caki‐1, and ACHN human renal cancer cell lines were treated with AFP 464 and 5F 203. We evaluated cytotoxicity by MTS assays, cell cycle arrest, and apoptosis by flow cytometry and corroborated a mechanism of action involving AhR signal transduction activation. Changes in migration properties by wound healing assays were investigated: 5F 203‐sensitive cells show decreased migration after treatment, therefore, we measured c‐Met phosphorylation by Western blot in these cells. A 5F 203 induced a decrease in cell viability which was more marked than AFP 464. This cytotoxicity was reduced after treatment with the AhR inhibitor α‐NF for both compounds indicating AhR signaling activation plays a role in the mechanism of action. A 5F 203 is sequestered by TK‐10 cells and induces CYP1A1 expression; 5F 203 potently inhibited migration of TK‐10, Caki‐1, and SN12C cells, and inhibited c‐Met receptor phosphorylation in TK‐10 cells. AhR ligand antitumor agents AFP 464 and 5F 203 represent potential new candidates for the treatment of renal cancer. A 5F 203 only inhibited migration of sensitive cells and c‐Met receptor phosphorylation in TK‐10 cells. c‐Met receptor signal transduction is important in migration and metastasis. Therefore, we consider that 5F 203 offers potential for the treatment of metastatic renal carcinoma. J. Cell. Biochem. 118: 4526–4535, 2017. ? 2017 Wiley Periodicals, Inc.
机译:摘要我们研究了两种AHR配体抗肿瘤剂,AFP 464和5F 203对人肾癌细胞的活性和机制,特别是研究其对细胞周期进展,细胞凋亡和迁移的影响。用AFP 464和5F 203处理TK-10,SN12C,CAKI-1和ACHN人肾癌细胞系。通过流式细胞术,通过MTS测定,细胞周期停滞和细胞凋亡,通过流式细胞术进行评估细胞毒性,并证实了涉及AHR的作用机制信号转导激活。研究了伤口愈合测定的迁移性质的变化:5F 203敏感细胞显示治疗后的迁移降低,因此我们通过这些细胞中的蛋白质印迹测量了C-Met磷酸化。 5F 203诱导比AFP 464更标记的细胞活力的降低。用AHR抑制剂α-NF处理后,所述αSHR信号激活的两种化合物在作用机制中起作用的作用,降低了这种细胞毒性。通过TK-10细胞螯合5F 203并诱导CYP1A1表达; 5F 203易于抑制TK-10,CAKI-1和SN12C细胞的迁移,并抑制TK-10细胞中的C-Met受体磷酸化。 AHR配体抗肿瘤剂AFP 464和5F 203代表患有治疗肾癌的潜在新候选者。 5F 203仅抑制TK-10细胞中敏感细胞和C-Met受体磷酸化的迁移。 C-Met受体信号转导在迁移和转移中是重要的。因此,我们认为5F 203提供了治疗转移性肾癌的潜力。 J.Cell。生物学习。 118:4526-4535,2017 2017年Wiley期刊,Inc。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号